Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$462.13 USD
+5.26 (1.15%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $461.89 -0.24 (-0.05%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth D Momentum C VGM
Fundamental Charts
About Return on Equity (TTM)
Vertex Pharmaceuticals Incorporated's return on equity, or ROE, is -3.36% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.65%. While this shows that VRTX has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
VRTX 462.13 +5.26(1.15%)
Will VRTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VRTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRTX
Stay Ahead of the Game With Vertex (VRTX) Q2 Earnings: Wall Street's Insights on Key Metrics
Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note
VRTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Harmony Biosciences Holdings, Inc. (HRMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Vertex Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
Other News for VRTX
Earnings week ahead: AMD, PLTR, PFE, DIS, O, ET, SHOP, GILD, MCD, CAT, VTRS, BP, UBER, CGC, and more
Vertex Pharmaceuticals (VRTX) Set to Release Q2 Earnings Report
Vertex Pharmaceuticals Q2 2025 Earnings Preview
KBRA Assigns Preliminary Ratings to VRTX 2025-HQ | VRTX Stock News
Here's How Much $1000 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth Today